How did 3M perform financially in 1993?

3M's 1993 results were mixed. Sales grew 1.0% to $14.02 billion, operating income declined 1.9% to $1.956 billion, and net income increased 2.5% to $1.263 billion, or $5.82 per share. Growth was held back by recessions in Europe and Japan, a strong U.S. dollar, a soft U.S. health care market, and aggressive pricing. Part of the net income increase came from a $36 million tax-settlement benefit and other non-recurring investment income.

What is the biggest legal risk facing 3M?

The largest disclosed legal risk is the silicone gel mammary implant litigation. As of year-end 1993, 3M faced 3,054 claims and lawsuits representing 8,842 claimants. Unlike other major manufacturers, 3M was not part of the February 1994 global settlement and is negotiating separately with plaintiffs. Management says its general counsel believes insurance coverage is sufficient and that the matter will not materially affect financial position, though the outcome remains uncertain given the early stage of the cases.

Is 3M's dividend safe and what are the shareholder returns?

The dividend appears secure. 3M has paid dividends for 78 consecutive years, and in February 1994 it raised the quarterly dividend 6% to 88 cents per share. Dividends paid in 1993 totaled $721 million, compared with operating cash flow of $2.09 billion. The company also repurchased $706 million of its stock in 1993 and approved a new buyback authorization of up to 12 million pre-split shares, along with a two-for-one stock split.

How strong is 3M's balance sheet?

The balance sheet is conservative. Total assets were $12.2 billion, long-term debt was $796 million, and total debt was 23% of stockholders' equity, up modestly from 22% a year earlier. The company maintains AAA long-term credit ratings, a current ratio of 1.9, and substantially funded its employee retirement plans. Capital expenditures declined 9.3% to $1.11 billion as management emphasized spending controls.

What challenges does 3M expect in 1994?

Management expects economic growth to improve modestly in the second half of 1994, supported by productivity gains and new products. However, it anticipates continued competitive pricing, particularly in the Information, Imaging and Electronic sector, and ongoing currency fluctuations that could again have a significant negative effect on results. The Life Sciences sector remains exposed to uncertainty over U.S. health care reform, and R&D and capital spending are expected to remain near 1993 levels.

MMM 10-K FY1993 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 7, 1994. Cited figures are marked; the original filing is the authoritative source.

3M's 1993 10-K shows a company navigating a difficult year with modest top-line growth but flat-to-down profitability.

Worldwide net sales rose only 1.0% to $14.02 billion^a, with U.S. sales up about 3% to $7.13 billion while international sales fell about 1% to $6.89 billion, as currency translation (roughly -6% internationally) and price pressure (roughly -2%) offset volume gains of 6%. Operating income fell 1.9% to $1.956 billion, and the operating margin slipped to 14.0% from 14.4%. Net income rose 2.5% to $1.263 billion, or $5.82 per share, but this gain was helped by a $36 million tax-settlement benefit and other non-recurring items in investment income.

Management estimates the stronger U.S. dollar cut 1993 net income by about $62 million^b, or 29 cents per share. Balance sheet and cash flow remained conservative. Total assets were $12.2 billion, long-term debt was $796 million, and total debt equaled 23% of stockholders' equity, with AAA long-term ratings maintained.

Operating cash flow was $2.09 billion^c, which covered $1.11 billion of capital expenditures and $721 million of dividends. Capital spending fell 9.3%, and the company repurchased $706 million of stock. Management highlighted several headwinds for 1994, including continued price competition in the Information, Imaging and Electronic sector, currency risk, and uncertainty over U.S. health care reform affecting Life Sciences.

Management also reported that the company announced a 6%^d dividend increase to 88 cents quarterly, a two-for-one stock split effective around April 1994, and a new authorization to repurchase up to 12 million pre-split shares. The principal risk flagged in the filing is litigation over silicone gel mammary implants. As of December 31, 1993, 3M was named in 3,054 claims and lawsuits covering 8,842 claimants.

3M was not included in the February 1994 global settlement announced by other defendants, and management says it is in discussions with plaintiffs' representatives. Management also states that its general counsel has opined that insurance coverage is sufficient, and no insurers have denied coverage, so the company believes the matter will not pose a material risk to its financial position. Environmental liabilities are also a continuing exposure, though management says these are accrued and reviewed quarterly.

02—Key points

Key Highlights

Net sales rose 1.0% to $14.02 billion, with U.S. sales up about 3% to $7.13 billion and international sales down about 1% to $6.89 billion due to currency effects.
Operating income fell 1.9% to $1.956 billion, and operating margin declined to 14.0% from 14.4%, reflecting price competition and negative currency translation.
Net income increased 2.5% to $1.263 billion ($5.82 per share), but the stronger U.S. dollar reduced 1993 net income by an estimated $62 million (29 cents per share).
Cash flow from operations was $2.09 billion, comfortably covering $1.11 billion in capital expenditures and $721 million in dividends, with the balance sheet still rated AAA.
Board raised the quarterly dividend 6% to 88 cents, approved a two-for-one stock split for shareholders of record March 15, 1994, and authorized repurchase of up to 12 million pre-split shares.
Silicone gel mammary implant litigation involves 3,054 claims covering 8,842 claimants, and 3M was excluded from the February 1994 global settlement, though management believes insurance coverage is adequate.
Management expects continued price pressure in the Information, Imaging and Electronic sector in 1994 and uncertainty from U.S. health care reform in the Life Sciences sector.

03—Questions

Frequently Asked Questions

How did 3M perform financially in 1993?
3M's 1993 results were mixed. Sales grew 1.0% to $14.02 billion, operating income declined 1.9% to $1.956 billion, and net income increased 2.5% to $1.263 billion, or $5.82 per share. Growth was held back by recessions in Europe and Japan, a strong U.S. dollar, a soft U.S. health care market, and aggressive pricing. Part of the net income increase came from a $36 million tax-settlement benefit and other non-recurring investment income.
What is the biggest legal risk facing 3M?
The largest disclosed legal risk is the silicone gel mammary implant litigation. As of year-end 1993, 3M faced 3,054 claims and lawsuits representing 8,842 claimants. Unlike other major manufacturers, 3M was not part of the February 1994 global settlement and is negotiating separately with plaintiffs. Management says its general counsel believes insurance coverage is sufficient and that the matter will not materially affect financial position, though the outcome remains uncertain given the early stage of the cases.
Is 3M's dividend safe and what are the shareholder returns?
The dividend appears secure. 3M has paid dividends for 78 consecutive years, and in February 1994 it raised the quarterly dividend 6% to 88 cents per share. Dividends paid in 1993 totaled $721 million, compared with operating cash flow of $2.09 billion. The company also repurchased $706 million of its stock in 1993 and approved a new buyback authorization of up to 12 million pre-split shares, along with a two-for-one stock split.
How strong is 3M's balance sheet?
The balance sheet is conservative. Total assets were $12.2 billion, long-term debt was $796 million, and total debt was 23% of stockholders' equity, up modestly from 22% a year earlier. The company maintains AAA long-term credit ratings, a current ratio of 1.9, and substantially funded its employee retirement plans. Capital expenditures declined 9.3% to $1.11 billion as management emphasized spending controls.
What challenges does 3M expect in 1994?
Management expects economic growth to improve modestly in the second half of 1994, supported by productivity gains and new products. However, it anticipates continued competitive pricing, particularly in the Information, Imaging and Electronic sector, and ongoing currency fluctuations that could again have a significant negative effect on results. The Life Sciences sector remains exposed to uncertainty over U.S. health care reform, and R&D and capital spending are expected to remain near 1993 levels.

04—Continue

← View all 10-K filings